Online inquiry

IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3470MR)

This product GTTS-WQ3470MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets pcrV gene. The antibody can be applied in Pseudomonas aeruginosa infections research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3470MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3464MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ2790MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ13271MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ3852MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ11783MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ15252MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ8491MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ13005MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW